Encapsulation of S-nitrosoglutathione: a transcriptomic validation, Drug Dev Ind Pharm. 2018, 17:1-28.

Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO, the encapsulation of GSNO into nanoparticles may be an interesting option. Methods: In this work, we have investigated the early (4h) and late (24h) transcriptomic response of THP-1 human monocytes cells to two doses (1.4 and 6 mM) of either free or EudragitVR nano-encapsulated GSNO using RNA microarray. Results: After exposure to free GSNO, genes mainly involved in apoptosis, cell differentiation, immune response and metabolic processes were differentially expressed. Although, cells exposed to free or encap- sulated GSNO behave differently, activation of genes involved in blood coagulation, immune response and cell cycle was observed in both conditions. Conclusions: These results suggest that the encapsulation of low doses of GSNO into EudragitVR nanopar- ticles leads to a progressive release of GSNO making this compound a possible oral therapy for several biomedical applications like inflammatory bowel diseases.